非小細胞肺癌 (NSCLC) 治療の世界市場 (2022年-2027年)：産業動向・COVID-19の影響・企業分析

世界の非小細胞肺癌 (NSCLC) 治療の市場規模は、2021年の　から、予測期間中は6.4％のCAGRで推移し、2027年には257億1,000万米ドルの規模に成長すると予測されています。

NSCLCの発生頻度は、すべての人口層と年齢層で拡大しており、NSCLC治療に対する需要が高まっています。また、先進国や新興国におけるNSCLCの診断数の増加や認知度の向上も同市場の成長を推進しています。さらに、喫煙者の割合の増加やアスベストなどの有害物質への曝露も市場の拡大に寄与しています。

当レポートでは、世界の非小細胞肺癌 (NSCLC) 治療の市場を調査し、市場概要、市場成長への影響因子の分析、市場規模の推移・予測、組織型・治療タイプ・医薬品クラス・エンドユーザー・地域など各種区分別の詳細分析、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査・調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長要因
• 課題

第5章 非小細胞肺癌 (NSCLC) 治療市場

第6章 市場シェア分析：非小細胞肺癌 (NSCLC) 治療

• 組織型別
• 治療タイプ別
• 医薬品クラス別
• エンドユーザー別
• 地域別

第7章 非小細胞肺癌 (NSCLC) 治療市場：組織型別

• 腺癌
• 扁平上皮癌
• 大細胞癌

第8章 非小細胞肺癌 (NSCLC) 治療市場：治療タイプ別

• 化学療法
• 免疫療法
• 放射線療法
• 手術
• 標的療法薬

第9章 非小細胞肺癌 (NSCLC) 治療市場：医薬品クラス別

• 血管新生阻害剤
• 上皮成長因子受容体遮断薬
• キナーゼ阻害剤
• 微小管安定剤
• 葉酸代謝拮抗剤
• PD-1/PD-L1阻害剤

第10章 非小細胞肺癌 (NSCLC) 治療市場：エンドユーザー別

• 一般医療・外科病院
• 専門病院
• クリニック
• その他

第11章 非小細胞肺癌 (NSCLC) 治療市場：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第12章 ポーターズファイブフォース分析

第13章 主要企業

• AbbVie Inc.
• Astellas Pharma
• AstraZeneca
• Avid Bioservices Inc.
• Bayer Healthcare
• Biogen Inc.
• Blueprint Medicines Corp
• Eli Lilly and Company
• Merck & co Inc.
• Novartis
• Pfizer Inc.

List of Figures

• Figure-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2016 - 2021
• Figure-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2022 - 2027
• Figure-03: Histology Type - Adenocarcinoma Market (Million US$), 2016 - 2021
• Figure-04: Histology Type - Forecast for Adenocarcinoma Market (Million US$), 2022 - 2027
• Figure-05: Histology Type - Squamous Cell Carcinoma Market (Million US$), 2016 - 2021
• Figure-06: Histology Type - Forecast for Squamous Cell Carcinoma Market (Million US$), 2022 - 2027
• Figure-07: Histology Type - Large Cell Carcinoma Market (Million US$), 2016 - 2021
• Figure-08: Histology Type - Forecast for Large Cell Carcinoma Market (Million US$), 2022 - 2027
• Figure-09: Treatment Type - Chemotherapy Market (Million US$), 2016 - 2021
• Figure-10: Treatment Type - Forecast for Chemotherapy Market (Million US$), 2022 - 2027
• Figure-11: Treatment Type - Immunotherapy Market (Million US$), 2016 - 2021
• Figure-12: Treatment Type - Forecast for Immunotherapy Market (Million US$), 2022 - 2027
• Figure-13: Treatment Type - Radiation Therapy Market (Million US$), 2016 - 2021
• Figure-14: Treatment Type - Forecast for Radiation Therapy Market (Million US$), 2022 - 2027
• Figure-15: Treatment Type - Surgery Market (Million US$), 2016 - 2021
• Figure-16: Treatment Type - Forecast for Surgery Market (Million US$), 2022 - 2027
• Figure-17: Treatment Type - Targeted Therapy Drugs Market (Million US$), 2016 - 2021
• Figure-18: Treatment Type - Forecast for Targeted Therapy Drugs Market (Million US$), 2022 - 2027
• Figure-19: Drug Class - Angiogenesis Inhibitor Market (Million US$), 2016 - 2021
• Figure-20: Drug Class - Forecast for Angiogenesis Inhibitor Market (Million US$), 2022 - 2027
• Figure-21: Drug Class - Epidermal Growth Factor Receptor Blocker Market (Million US$), 2016 - 2021
• Figure-22: Drug Class - Forecast for Epidermal Growth Factor Receptor Blocker Market (Million US$), 2022 - 2027
• Figure-23: Drug Class - Kinase Inhibitor Market (Million US$), 2016 - 2021
• Figure-24: Drug Class - Forecast for Kinase Inhibitor Market (Million US$), 2022 - 2027
• Figure-25: Drug Class - Microtubule Stabilizer Market (Million US$), 2016 - 2021
• Figure-26: Drug Class - Forecast for Microtubule Stabilizer Market (Million US$), 2022 - 2027
• Figure-27: Drug Class - Folate Antimetabolites Market (Million US$), 2016 - 2021
• Figure-28: Drug Class - Forecast for Folate Antimetabolites Market (Million US$), 2022 - 2027
• Figure-29: Drug Class - PD-1/ PD-L1 Inhibitor Market (Million US$), 2016 - 2021
• Figure-30: Drug Class - Forecast for PD-1/ PD-L1 Inhibitor Market (Million US$), 2022 - 2027
• Figure-31: End User - General Medical & Surgical Hospitals Market (Million US$), 2016 - 2021
• Figure-32: End User - Forecast for General Medical & Surgical Hospitals Market (Million US$), 2022 - 2027
• Figure-33: End User - Specialty Hospitals Market (Million US$), 2016 - 2021
• Figure-34: End User - Forecast for Specialty Hospitals Market (Million US$), 2022 - 2027
• Figure-35: End User - Clinics Market (Million US$), 2016 - 2021
• Figure-36: End User - Forecast for Clinics Market (Million US$), 2022 - 2027
• Figure-37: End User - Others Market (Million US$), 2016 - 2021
• Figure-38: End User - Forecast for Others Market (Million US$), 2022 - 2027
• Figure-39: North America - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
• Figure-40: North America - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
• Figure-41: Europe - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
• Figure-42: Europe - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
• Figure-43: Asia-Pacific - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
• Figure-44: Asia-Pacific - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
• Figure-45: Rest of the World - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
• Figure-46: Rest of the World - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
• Figure-47: AbbVie Inc. - Global Revenue (Million US$), 2016 - 2021
• Figure-48: AbbVie Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-49: Astellas Pharma - Global Revenue (Million US$), 2016 - 2021
• Figure-50: Astellas Pharma - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-51: AstraZeneca - Global Revenue (Million US$), 2016 - 2021
• Figure-52: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-53: Avid Bioservices Inc. - Global Revenue (Million US$), 2016 - 2021
• Figure-54: Avid Bioservices Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-55: Bayer Healthcare - Global Revenue (Million US$), 2016 - 2021
• Figure-56: Bayer Healthcare - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-57: Biogen Inc. - Global Revenue (Million US$), 2016 - 2021
• Figure-58: Biogen Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-59: Blueprint Medicines Corp - Global Revenue (Million US$), 2016 - 2021
• Figure-60: Blueprint Medicines Corp - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-61: Eli Lilly and Company - Global Revenue (Million US$), 2016 - 2021
• Figure-62: Eli Lilly and Company - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-63: Merck & co Inc. - Global Revenue (Million US$), 2016 - 2021
• Figure-64: Merck & co Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-65: Novartis - Global Revenue (Million US$), 2016 - 2021
• Figure-66: Novartis - Forecast for Global Revenue (Million US$), 2022 - 2027
• Figure-67: Pfizer Inc. - Global Revenue (Million US$), 2016 - 2021
• Figure-68: Pfizer Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables

• Table-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2016 - 2021
• Table-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2022 - 2027
• Table-03: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2016 - 2021
• Table-04: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2022 - 2027
• Table-05: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2016 - 2021
• Table-06: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2022 - 2027
• Table-07: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2016 - 2021
• Table-08: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2022 - 2027
• Table-09: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2016 - 2021
• Table-10: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2022 - 2027

Global Non-Small Cell Lung Cancer (NSCLC) Market will reach US$ 25.71 Billion in 2027. Globally, lung cancer is one of the most frequent types of cancer, with two distinct subtypes. The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC). Furthermore, lung cancer, as one of the most common malignancies in the world, is responsible for a considerable number of deaths globally. As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.

COVID-19 Impact on Non-Small Cell Lung Cancer Treatment (NSCLC) Industry:

Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic. Even for patients who were non-COVID-19, the disturbance of regular hospital services, such as imaging and treatment appointments, had a significant impact on the physical and mental well-being of these patients. The stress placed on the availability of medical resources and hospitals has reduced the clinical admissions to most other departments, including oncology departments. Consequently, the benefits some cancer patients could have received have been compromised due to treatment delay declining the market in 2020.

Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size has reached US$ 17.75 Billion in 2021

The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries. Other reasons contributing to the expansion of the non-small cell lung cancer treatments market include an increase in the proportion of smokers and exposure to toxins such as asbestos. According to our estimates, the Non-Small Cell Lung Cancer (NSCLC) Market will grow at a 6.4% CAGR from 2021 to 2027.

Adenocarcinoma Is the Most Prevalent Segment Histologically:

Our report classified the histological segment into three categories: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared to the other two forms, adenocarcinoma is the most common and is found in the cells responsible for mucous secretion in the outer lung sections. Furthermore, Squamous Cell Carcinoma, located in the squamous cells near the bronchus in the middle of the lungs, is one of the fastest expanding segments in the market. Large cell carcinoma, also known as undifferentiated carcinoma, can develop in any section of the lungs, is the fastest-growing, and is the most difficult to cure.

Immunotherapy Market Share is Estimated to Be the Largest:

By treatment, immunotherapy is expected to have the most significant market share. According to our estimates, the targeted therapy category will grow during the projection period. The increasing number of product launches, particularly in the immunotherapy area, is credited with the market domination. Immunotherapy is currently being used more widely in emerging countries, owing to improved patient outcomes resulting from effective treatment.

Regional Analysis:

In our report, we have examined the regions like North America, Europe, Asia-Pacific, Rest of The World. Lung cancer is becoming more common, and innovative therapies and are becoming more widely used, making the North America, Europe & Asia Pacific the most powerful region worldwide. Due to a rise in lung cancer diagnoses, India and China in the Asia Pacific region are seeing growth in NSCLC therapies. Chemotherapy is the most common kind of treatment in these underdeveloped countries. However, advanced immunotherapies and targeted medicines are seeing rising adoption and investment in nations like United States, Germany, United Kingdom, and Japan.

Key Market Players:

Our report examines AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & Co Inc., Novartis, and Pfizer Inc. as leading players in the Non-Small Cell Lung Cancer Treatment (NSCLC) Market. The majority of significant market players are also concentrating on continuous advancements in advanced therapies and improving the efficacy of existing medicines. These businesses are receiving product approvals as well.

Renub Research latest report "Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Histology Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), End User (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics, Others), Region (North America, Europe, Asia-Pacific, Rest of The World), Companies (AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & co Inc., Novartis, Pfizer Inc.)" provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.

Histology Type - Market has been covered from 3 viewpoints:

• 1. Adenocarcinoma
• 2. Squamous Cell Carcinoma
• 3. Large Cell Carcinoma

Treatment Type - Market has been covered from 5 viewpoints:

• 1. Chemotherapy
• 2. Immunotherapy
• 3. Radiation Therapy
• 4. Surgery
• 5. Targeted Therapy Drugs

Drug Class - Market has been covered from 6 viewpoints:

• 1. Angiogenesis Inhibitor
• 2. Epidermal Growth Factor Receptor Blocker
• 3. Kinase Inhibitor
• 4. Microtubule Stabilizer
• 5. Folate Antimetabolites
• 6. PD-1/ PD-L1 Inhibitor

End User - Market has been covered from 4 viewpoints:

• 1. General Medical & Surgical Hospitals
• 2. Specialty Hospitals
• 3. Clinics
• 4. Others

Region - Market has been covered from 4 viewpoints:

• 1. North America
• 2. Europe
• 3. Asia-Pacific
• 4. Rest of The World

Company Insights:

• Overview
• Recent Development
• Revenue

Key Players:

• 1. AbbVie Inc.
• 2. Astellas Pharma
• 3. AstraZeneca
• 4. Avid Bioservices Inc.
• 5. Bayer Healthcare
• 6. Biogen Inc.
• 7. Blueprint Medicines Corp
• 8. Eli Lilly and Company
• 9. Merck & co Inc.
• 10. Novartis
• 11. Pfizer Inc.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market

6. Market Share Analysis - Non-Small Cell Lung Cancer Treatment (NSCLC)

• 6.1 By Histology Type
• 6.2 By Treatment Type
• 6.3 By Drug Class
• 6.4 By End User
• 6.5 By Region

7. Histology Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

• 7.1 Adenocarcinoma
• 7.2 Squamous Cell Carcinoma
• 7.3 Large Cell Carcinoma

8. Treatment Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

• 8.1 Chemotherapy
• 8.2 Immunotherapy
• 8.3 Radiation Therapy
• 8.4 Surgery
• 8.5 Targeted Therapy Drugs

9. Drug Class - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

• 9.1 Angiogenesis Inhibitor
• 9.2 Epidermal Growth Factor Receptor Blocker
• 9.3 Kinase Inhibitor
• 9.4 Microtubule Stabilizer
• 9.5 Folate Antimetabolites
• 9.6 PD-1/ PD-L1 Inhibitor

10. End User - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

• 10.1 General Medical & Surgical Hospitals
• 10.2 Specialty Hospitals
• 10.3 Clinics
• 10.4 Others

11. Region - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

• 11.1 North America
• 11.2 Europe
• 11.3 Asia-Pacific
• 11.4 Rest of The World

12. Porters Five Forces

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13. Key Players

• 13.1 AbbVie Inc.
  • 13.1.1 Overview
  • 13.1.2 Recent Development
  • 13.1.3 Revenue
• 13.2 Astellas Pharma
  • 13.2.1 Overview
  • 13.2.2 Recent Development
  • 13.2.3 Revenue
• 13.3 AstraZeneca
  • 13.3.1 Overview
  • 13.3.2 Recent Development
  • 13.3.3 Revenue
• 13.4 Avid Bioservices Inc.
  • 13.4.1 Overview
  • 13.4.2 Recent Development
  • 13.4.3 Revenue
• 13.5 Bayer Healthcare
  • 13.5.1 Overview
  • 13.5.2 Recent Development
  • 13.5.3 Revenue
• 13.6 Biogen Inc.
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Revenue
• 13.7 Blueprint Medicines Corp
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Revenue
• 13.8 Eli Lilly and Company
  • 13.8.1 Overview
  • 13.8.2 Recent Development
  • 13.8.3 Revenue
• 13.9 Merck & co Inc.
  • 13.9.1 Overview
  • 13.9.2 Recent Development
  • 13.9.3 Revenue
• 13.10 Novartis
  • 13.10.1 Overview
  • 13.10.2 Recent Development
  • 13.10.3 Revenue
• 13.11 Pfizer Inc.
  • 13.11.1 Overview
  • 13.11.2 Recent Development
  • 13.11.3 Revenue